Stocks Industrials BIO
NYSE · IndustrialsBio-Rad Laboratories, Inc. (BIO)
Bio-Rad Laboratories, Inc. brought in $2.6B of revenue over the twelve months to September 30, 2026, up 1.4% from a year earlier. Net income was $1B, a net margin of 39.5%. Operating cash flow minus capital spending left $374.6M of free cash flow in fiscal 2025. At September 30, 2026 it held $465.3M in cash against $1.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Bio-Rad Laboratories, Inc.
- Net worth
- Bio-Rad Laboratories, Inc. has a market value (market cap) of $10.4B at the latest share price, and shareholders' equity of $7.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.6B (+0.7% year on year), with net income of $759.9M. Over the 12 months to September 30, 2026: revenue $2.6B, net income $1B.
- Cash flow
- In fiscal 2025 operations brought in $532.2M of cash; after $157.6M of capital spending, free cash flow was $374.6M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Bio-Rad Laboratories, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Bio-Rad Laboratories, Inc. does
Bio-Rad Laboratories, Inc. is registered with the SEC under industry code SIC 3826 (Laboratory Analytical Instruments). Its shares trade on NYSE under the ticker BIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.6B | $759.9M | $27.85 | $374.6M |
| 2024 | $2.6B | -$1.8B | -$65.36 | $289.6M |
| 2023 | $2.7B | -$637.3M | -$21.82 | $218.2M |
| 2022 | $2.8B | -$3.6B | -$121.79 | $81.6M |
| 2021 | $2.9B | $4.3B | $140.83 | $535.7M |
| 2020 | $2.5B | $3.8B | $126.47 | $476.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BIO ranks in Industrials
Latest SEC filings
What Bio-Rad Laboratories, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 0.5% to $656.4M versus the same quarter last year; diluted EPS $17.02 versus -$12.70.
- November 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was flat at $651M versus the same quarter last year; diluted EPS $13.85 versus $11.67.
- August 4, 2026
- May 13, 2026
- April 30, 2026
- April 30, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 1.1% to $592.1M versus the same quarter last year; diluted EPS -$19.55 versus $2.29.
- April 30, 2026
- April 24, 2026
- March 26, 2026Passive stake changed SCHEDULE 13G/A
What is BIO worth? A DCF from its reported cash flow
Insider trades
What the people running Bio-Rad Laboratories, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 44 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 24, 2026 | DiVincenzo Jonathan P.President & COO | Exercised options | 1,869 | - |
| October 24, 2026 | DiVincenzo Jonathan P.President & COO | Shares withheld for tax | 951 | $351.8K |
| October 20, 2026 | Evran SedatEVP, Global Supply Chain | Exercised options | 1,044 | - |
| October 20, 2026 | Evran SedatEVP, Global Supply Chain | Shares withheld for tax | 487 | $172.6K |
| September 6, 2026 | Schwartz Norman DChairman & CEO, Director, 10% owner | Exercised options | 3,455 | - |
| September 6, 2026 | Schwartz Norman DChairman & CEO, Director, 10% owner | Shares withheld for tax | 1,854 | $715.8K |
| September 6, 2026 | Lakkaraju Roop KalyanEVP, Chief Financial Officer | Exercised options | 1,536 | - |
| September 6, 2026 | Lakkaraju Roop KalyanEVP, Chief Financial Officer | Shares withheld for tax | 782 | $301.9K |
Who owns BIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Norman D. Schwartz13D, may seek influence with 3 related filers | 97.2% | October 30, 2025 |
| First Eagle Investment Management, LLC13G, passive with 1 related filers | 11.4% | August 6, 2025 |
| Bio-Rad Laboratories, Inc13G, passive | 9.7% | March 4, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 398 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| First Eagle Investment Management, LLC | 5,212,438 | +2,609,666 |
| BlackRock, Inc. | 1,698,929 | +18,869 |
| Dimensional Fund Advisors LP | 944,548 | -144,775 |
| Vanguard Capital Management LLC | 826,972 | -4,193 |
| Ariel Investments, LLC | 816,751 | +30,790 |
| Vanguard Portfolio Management LLC | 816,198 | -12,988 |
| Earnest Partners LLC | 580,752 | -7,979 |
| State Street Corp | 571,762 | +12,192 |
| Bank of America Corp | 490,412 | +45,455 |
| Assenagon Asset Management S.A. | 466,454 | +318,620 |
| Capital World Investors | 462,457 | +12,457 |
| Capital Research Global Investors | 443,483 | +57,904 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 418,884 | -7,154 |
| First Pacific Advisors, LP | 401,861 | -5,497 |
| Geode Capital Management, LLC | 347,575 | -17,107 |
| Nomura Holdings Inc | 328,897 | +111,555 |
| UBS Group AG | 308,325 | -46,040 |
| Sei Investments Co | 273,377 | -14,535 |
| Barclays PLC | 267,634 | -11,201 |
| Deerfield Management Company, L.P. | 226,070 | 0 |
Insiders
13 insiders reported holding 472,042 shares in total, about $183.3M at the last price.
| Holder | Shares |
|---|---|
| Schwartz Norman DChairman & CEO, Director, 10% owner | 449,019 |
| Evran SedatEVP, Global Supply Chain | 4,160 |
| Lakkaraju Roop KalyanEVP, Chief Financial Officer | 4,151 |
| DiVincenzo Jonathan P.President & COO | 2,881 |
| Barry JamesEVP, President, LSG | 2,025 |
| Engelhardt Eva AnetteEVP, President, CDG | 1,828 |
| Allison SchwartzDirector | 1,734 |
| Enloe Courtney CEVP, General Counsel & Sec | 1,652 |
| Mehta RajatEVP, GBL Commercial Operations | 1,232 |
| Hinckley Greg KDirector | 1,215 |
Questions about BIO
What does Bio-Rad Laboratories, Inc. do?
Bio-Rad Laboratories, Inc. is a company in the Industrials sector, listed on NYSE as BIO. Its shares trade on NYSE under the ticker BIO.
What is Bio-Rad Laboratories, Inc.'s net worth?
Bio-Rad Laboratories, Inc. has a market value (market cap) of $10.4B at the latest share price, and shareholders' equity of $7.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bio-Rad Laboratories, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $1B on revenue of $2.6B, a net margin of 39.5%.
How much revenue does Bio-Rad Laboratories, Inc. make?
Over the twelve months to September 30, 2026 Bio-Rad Laboratories, Inc. reported revenue of $2.6B. That is 1.4% more than a year earlier.
When did Bio-Rad Laboratories, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 9, 2026.
When is Bio-Rad Laboratories, Inc.'s next earnings report?
Bio-Rad Laboratories, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BIO with
Follow BIO
Get an email when Bio-Rad Laboratories, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bio-Rad Laboratories, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.